Refractory Acute Myeloid Leukemia Aml clinical trials

Explore recruiting refractory acute myeloid leukemia aml clinical trials.

Recruiting refractory acute myeloid leukemia aml studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Refractory Acute Myeloid Leukemia Aml trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).

Spain, Hungary, Czechia, France, Italy, Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

MAATEO: A phase 1 study in patients with hematological malignancies to evaluate safety, tolerability and efficacy of Karonudib

Sweden, Denmark

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An adaptive open-label multicentre phase 1/2 trial, to determine the recommended phase 2 dose of CCTx-001, and to assess safety, tolerability, and clinical activity in patients with relapsed/refractory acute myeloid leukaemia (RESOLVE AML 001)

Germany, Spain, Sweden, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

APTIVATE Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Poland, Germany, Sweden, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Spain, Italy, France, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Refractory Acute Myeloid Leukemia Aml trials by city

Refractory Acute Myeloid Leukemia Aml in Toronto Refractory Acute Myeloid Leukemia Aml in Vancouver Refractory Acute Myeloid Leukemia Aml in Montreal Refractory Acute Myeloid Leukemia Aml in Calgary Refractory Acute Myeloid Leukemia Aml in Edmonton Refractory Acute Myeloid Leukemia Aml in Ottawa Refractory Acute Myeloid Leukemia Aml in Winnipeg Refractory Acute Myeloid Leukemia Aml in Quebec City Refractory Acute Myeloid Leukemia Aml in Hamilton Refractory Acute Myeloid Leukemia Aml in Kitchener Refractory Acute Myeloid Leukemia Aml in London Refractory Acute Myeloid Leukemia Aml in Halifax Refractory Acute Myeloid Leukemia Aml in New York Refractory Acute Myeloid Leukemia Aml in Los Angeles Refractory Acute Myeloid Leukemia Aml in Chicago Refractory Acute Myeloid Leukemia Aml in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease